ArticleFrontiers in cell and developmental biology2026
Methylglyoxal hampers the angiogenic capacity of human retinal endothelial cells modifying cell transcriptome with the contribution of NRSF/REST.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The functional impairment of retinal microvascular cells is an early and central event in diabetic retinopathy (DR). Methylglyoxal (MGO), the most reactive precursor of advanced glycation end products (AGEs), has been implicated in vascular injury and neuro-retinal dysfunction. Its direct effects on retinal endothelial cells and underlying molecular mechanisms remain poorly understood. Methods: Human retinal endothelial cells (hRECs) were exposed to MGO and the effect of sublethal doses on the proangiogenic function was evaluated by migration, tube formation and pericyte recruitment assays. MGO derived AGEs were evaluated by western blot. Transcriptome and miRNome profiling were performed to identify gene expression and microRNA perturbations. Integrative Results: The exposure of hRECs to MGO for 72 h is sufficient to increase protein glycation adducts, impair the migration, tube-formation and the recruitment of pericytes. Transcriptome and miRNome analyses highlight that MGO induces extensive transcriptional perturbations, related to gene expression regulation, cell cycle, cell death and vasculature development. Among the identified transcriptional regulators, Neuron-Restrictive Silencer Factor/RE1-Silencing Transcription Factor (NRSF/REST) emerges as a candidate mediator, with binding sites enriched in 56% of deregulated genes. NRSF/REST expression markedly increases after 24 h of MGO treatment, suggesting it is an early event of the exposure to MGO. Protein-protein interaction network analysis prioritized NRSF/REST as a central node linking key MGO-responsive pathways. Accordingly, NRSF/REST knockdown is associated with the reduction of Conclusion: These findings demonstrate that MGO exposure disrupts endothelial function and transcriptional homeostasis in hRECs, identifying NRSF/REST as a contributor to MGO-induced endothelial dysfunction and supporting further investigations of the MGO/NRSF-REST axis as a potential therapeutic target for DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.